Monitoring the bioavailability of FEIBA with a thrombin generation assay.
about
Treatment and Prevention of Bleeds in Haemophilia Patients with Inhibitors to Factor VIII/IXRandomized comparison of prophylaxis and on-demand regimens with FEIBA NF in the treatment of haemophilia A and B with inhibitors.A first-in-human phase 1 study of ACE910, a novel factor VIII-mimetic bispecific antibody, in healthy subjects.Acquired hemophilia A: emerging treatment options.Haemophilia and thrombophilia: an unexpected association!FEIBA: mode of action.Thrombin generation assay and other universal tests for monitoring haemophilia therapy.Design and characterization of an APC-specific serpin for the treatment of hemophilia.The measurement and application of thrombin generation.The diagnosis and management of factor VIII and IX inhibitors: a guideline from the United Kingdom Haemophilia Centre Doctors Organisation.Patients Referred for Bleeding Symptoms of Unknown Cause: Does Evaluation of Thrombin Generation Contribute to Diagnosis?Basic aspects of bypassing agents.Diagnostic approach to inherited bleeding disorders.Treatment of acquired hemophilia A.Haemophilia therapies.International workshop on immune tolerance induction: consensus recommendations.Surgical interventions in a cohort of patients with haemophilia A and inhibitors: an experiential retrospective chart review.New advances in the therapeutic and laboratory management of patients with haemophilia and inhibitors.Epidemiology and general guidelines of the management of acquired haemophilia and von Willebrand syndrome.Thrombin generation testing in haemophilia comprehensive care centres.Clinical advances in hemophilia management.Management of acquired haemophilia A.Sequential therapy with activated prothrombin complex concentrates and recombinant activated factor VII to treat unresponsive bleeding in patients with hemophilia and inhibitors: a single center experience.Advances in bypassing agent therapy for hemophilia patients with inhibitors to close care gaps and improve outcomesAcquired hemophilia A: Updated review of evidence and treatment guidance.Pro- and anticoagulant factors facilitate thrombin generation and balance the haemostatic response to FEIBA(®) in prophylactic therapy.The efficacy of bypassing agents in surgery of hemophilia patients with inhibitors.Two-incision laparoscopic appendectomy for a severe hemophilia A child patient with coagulation factor VII deficiency: Case report and review of literature.Prothrombin complex concentrate vs fresh frozen plasma for reversal of dilutional coagulopathy in a porcine trauma model.The measurement of low levels of factor VIII or factor IX in hemophilia A and hemophilia B plasma by clot waveform analysis and thrombin generation assay.Manipulation of prothrombin concentration improves response to high-dose factor VIIa in a cell-based model of haemophilia.Thrombin generation as objective parameter of treatment response in patients with severe haemophilia A and high-titre inhibitors.A retrospective postlicensure survey of FEIBA efficacy and safety.Evaluation of the use of global haemostasis assays to monitor treatment in factor XI deficiency.Tissue factor pathway inhibitor in activated prothrombin complex concentrates (aPCC) moderates the effectiveness of therapy in some severe hemophilia A patients with inhibitor.A difficult case of acquired haemophilia with concomitant Evan's Syndrome presenting with acute subdural haematoma.Current use of by-passing agents in Europe in the management of acute bleeds in patients with haemophilia and inhibitors.Impact of different inhibitor reactivities with commercial factor VIII concentrates on thrombin generation.Re: Discordant pair analysis of rFVIIa and pd-aPCC response.Stabilization of fibrin clots by activated prothrombin complex concentrate and tranexamic acid in FVIII inhibitor plasma.
P2860
Q33608230-2E01D16C-A8D0-4D43-827B-B92BE6EE9C55Q34436796-7F61A76D-0FDA-440F-844F-81F1602C16D3Q34503723-74711B64-63FF-40DF-9378-E62D838A8B3FQ35605896-2EE9C874-8E4C-4152-8FD7-7E0EE39F1F14Q35824844-A8321D0D-CC3F-4FAB-A337-398F17304BAFQ35895858-6BCF1523-E665-477C-916E-BD0E2A4E4A4FQ35895866-9B57AE13-778B-410A-91B6-89090E0ECE2BQ36176667-4ABEDE8A-4D99-4FFD-9BBC-75DC1E8CB293Q36237649-F9407E67-0943-444A-AADE-B42FD5FD9F1FQ36480548-AC4EF3AA-4DF5-4886-9918-1DAF69235966Q36630802-60436633-0223-4E9A-90CE-A4FC890CF0CFQ36661832-29E5328E-F760-439C-9789-676F8513FBB9Q36715734-144510FC-801C-425F-B6B4-266B8DF42C4DQ36802699-CBC06CA2-861B-4BC5-8609-D4488D81F961Q36810282-9F7F56BB-A82D-4419-9585-1952E85FBDBDQ36861097-122B3376-44EB-4B86-90A9-D7DA0417FC27Q36945945-830361D5-A4C6-4D21-9213-24B8A631A3ABQ37169669-E479983C-8681-4FFD-BD85-7339E3784C90Q37176491-77A07883-C46B-47FA-945C-810C2C8FD48CQ37589662-1DD05E76-F715-4A29-8947-1A29ECAB5682Q37900933-99336CAD-81F8-4656-9E2E-94CE892AC1DFQ37903945-E5B6514E-5FFD-4FE7-9F14-7D68E20A30C2Q38182105-E8AFD16B-5EAD-4C22-A519-A6006B03200FQ38235951-B37518A6-8475-434E-8359-C075EEF3C0B1Q38805567-D652B3AD-F1D3-4ECA-8F38-C01FF3D9B76EQ39995569-F42D766B-737B-4C5D-856D-BED8875317A8Q41210614-AF5EF4D5-0516-4549-8BAC-DDC7F6B1CAB3Q41922244-73C3E61C-16B2-4B5C-83FD-E895D375B31CQ43180952-86C4ED30-40E3-4EFD-B2DD-1C5CF1C262F7Q45855320-DED9496B-832A-4FD5-8F2F-CD83C96B85DCQ45859169-7757A29F-60B1-41A1-852D-2AE8B2FF56A1Q45859196-AE26DE34-E0FF-4708-A97F-340B0EE6DBFBQ45859618-21CC113C-52E3-4E1C-B81D-6F16558C5E2AQ45861959-E67C4681-E5AA-401D-95E7-32A6ECC4CAF3Q45863755-41428471-555D-4513-BFEF-C948959C2A27Q45864570-132BEBC9-0B6E-4260-880A-8F23F7A6047EQ45864880-F2A270A0-C3F6-4A74-8354-D4AC295D3C0AQ45864893-B3A89E7F-526C-4681-A80E-F95F36BFD5E2Q45867408-6B238F99-46F3-474A-AB9F-617EF0903563Q45867938-8C5E3E56-F7BC-4454-B3AD-D4176AF94CC4
P2860
Monitoring the bioavailability of FEIBA with a thrombin generation assay.
description
2003 nî lūn-bûn
@nan
2003年の論文
@ja
2003年学术文章
@wuu
2003年学术文章
@zh
2003年学术文章
@zh-cn
2003年学术文章
@zh-hans
2003年学术文章
@zh-my
2003年学术文章
@zh-sg
2003年學術文章
@yue
2003年學術文章
@zh-hant
name
Monitoring the bioavailability of FEIBA with a thrombin generation assay.
@en
Monitoring the bioavailability of FEIBA with a thrombin generation assay.
@nl
type
label
Monitoring the bioavailability of FEIBA with a thrombin generation assay.
@en
Monitoring the bioavailability of FEIBA with a thrombin generation assay.
@nl
prefLabel
Monitoring the bioavailability of FEIBA with a thrombin generation assay.
@en
Monitoring the bioavailability of FEIBA with a thrombin generation assay.
@nl
P2093
P2860
P1476
Monitoring the bioavailability of FEIBA with a thrombin generation assay
@en
P2093
E Berntorp
H P Schwarz
J Astermark
P L Turecek
P2860
P304
P356
10.1046/J.1538-7836.2003.00450.X
P577
2003-11-01T00:00:00Z